| Literature DB >> 29642533 |
Alberto Leonardi1, Laura Penta2, Marta Cofini3, Lucia Lanciotti4, Nicola Principi5, Susanna Esposito6.
Abstract
Background: Autoimmune hypothyroidism (Hashimoto thyroiditis; HT) is the most common postnatal thyroid disease. Clinical manifestations of HT vary according to disease severity. Due to the pleiotropic effects of thyroid hormone, less common signs and symptoms of HT can occur, leading to a delay in diagnosis. Case presentation: A 9-year-old girl of Indian origin was admitted for a one-week history of widespread myalgia, fatigue, muscle weakness, difficulty walking, and a significant increase in weight (approximately 2 kg) without any changes in daily habits. The only relevant medical history was several intermittent vaginal bleeding episodes since four years of age. Breast development was consistent with Tanner stage 2 without pubic or axillary hair; while height and weight were at the 10th percentile and the 38th percentile; respectively. Bone age from a left wrist X-ray was delayed 1 year. Pelvic ultrasonography revealed a uterine body/neck ratio of >1 (pubertal stage) and multifollicular ovaries. Her external genitalia had a childlike appearance. Laboratory examinations showed an increased thyroid-stimulating hormone, decreased free thyroxine, and positive anti-thyroglobulin antibody titres, as well as elevation of creatine phosphokinase, myoglobin, lactate dehydrogenase, serum aspartate aminotransferase, hypercholesterolemia, and a basal serum prolactin near the upper limit of normal. Follicle stimulating hormone and estradiol were slightly and significantly elevated, respectively. Thyroid ultrasound showed an increased gland size with irregular echostructures and high vascularization. Levothyroxine replacement therapy led to complete normalization of clinical and laboratory findings, including rhabdomyolysis indices. No further vaginal bleeding episodes were reported.Entities:
Keywords: Hashimoto thyroiditis; Van Wyk-Grumbach syndrome; hypothyroidism; pseudoprecocious puberty; rhabdomyolysis
Mesh:
Substances:
Year: 2018 PMID: 29642533 PMCID: PMC5923746 DOI: 10.3390/ijerph15040704
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Laboratory results on admission and during follow-up from the time of initiation of levothyroxine therapy.
| Test (Reference Interval) | 0 Day | 1 Week | 1 Month | 3 Months |
|---|---|---|---|---|
| TSH (0.340–5.600 µIU/mL) | 357 | 6.37 | 1.49 | |
| fT4 (0.54–1.24 ng/dL) | 0.26 | 1.00 | 0.89 | |
| Anti-TPO antibodies (0.0–9.0 UI/mL) | 3.4 | |||
| Anti-thyroglobulin antibodies (0–4.9 UI/mL) | 73.7 | |||
| FSH (1.6–9.6 mUI/mL) | 10.2 | |||
| LH (1–11 mIU/mL) | 0.10 | |||
| Estradiol (20–60 pg/mL) | 86 | |||
| SGOT (<45 UI/L) | 105 | 44 | ||
| LDH (225–450 UI/L) | 748 | 496 | 436 | |
| CPK (0–180 UI/L) | 3395 | 392 | 170 | |
| Myoglobin (14.3–65.8 ng/mL) | 76 | 52 | ||
| Total cholesterol (95th percentile: 197 mg/dL) | 294 | 209 | 156 |
TSH: thyroid-stimulating hormone; fT4: free thyroxine; TPO: thyroid peroxidase; FSH: follicle stimulating hormone; LH, luteinizing hormone; SGOT: aspartate aminotransferase; LDH, lactate dehydrogenase; CPK, creatine phosphokinase.
Figure 1A thyroid ultrasound with evidence of an enlarged thyroid gland (total volume 10 mL) with non-homogeneous echotexture.